Valuation: Mendus AB

Market Cap 342M 34.52M 30.97M 28.64M 25.93M 48.45M 3.29B 49.04M 136M 1.72B 130M 127M 5.46B P/E 2026 *
-3.51x
P/E 2027 * -5.33x
Enterprise Value 364M 36.67M 32.9M 30.42M 27.55M 51.47M 3.49B 52.09M 145M 1.83B 138M 135M 5.8B EV / Sales 2026 *
47.6x
EV / Sales 2027 * 0.99x
Free-Float
35.25%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week+4.30%
Current month-15.77%
1 month-17.97%
3 months-19.21%
6 months+5.33%
Current year-4.64%
1 week 4.77
Extreme 4.77
6
1 month 4.77
Extreme 4.77
6.42
Current year 3.86
Extreme 3.86
8.49
1 year 3.86
Extreme 3.86
8.49
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 2021-03-15
Chief Executive Officer 76 2019-12-12
Director of Finance/CFO 60 2021-02-27
Director TitleAgeSince
Chairman 52 2021-01-21
Director/Board Member 64 2019-12-31
Director/Board Member 74 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/28/22 Buy

Chief Technology Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%+4.30%-20.18%-32.75% 34.52M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.08%-0.08%+44.86%+143.27% 38.05B
Weighted average by Cap. +3.23%-0.50%+47.53%+161.45%

Financials

2026 *2027 *
Net sales 7.63M 770K 691K 638K 578K 1.08M 73.3M 1.09M 3.04M 38.36M 2.89M 2.83M 122M 172M 17.36M 15.57M 14.4M 13.04M 24.36M 1.65B 24.66M 68.57M 865M 65.14M 63.77M 2.75B
Net income -99.17M -10M -8.97M -8.29M -7.51M -14.03M -952M -14.2M -39.5M -498M -37.52M -36.73M -1.58B -33.34M -3.36M -3.02M -2.79M -2.53M -4.72M -320M -4.78M -13.28M -168M -12.62M -12.35M -532M
Net Debt 21.31M 2.15M 1.93M 1.78M 1.61M 3.02M 205M 3.05M 8.49M 107M 8.06M 7.89M 340M -172M -17.34M -15.56M -14.39M -13.03M -24.34M -1.65B -24.64M -68.51M -864M -65.08M -63.71M -2.74B
Projected Income Statement - Annual - Mendus AB
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
26-10-28 SEK 5.340 -0.19% 9,496
26-10-27 SEK 5.350 -2.55% 12,669
26-10-26 SEK 5.490 -1.96% 50,129
26-10-23 SEK 5.600 +5.66% 28,171
26-10-22 SEK 5.300 +2.12% 902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Mendus AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.340SEK
Average target price
33.95SEK
Spread / Average Target
+535.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mendus AB
  1. Stock Market
  2. Stocks
  3. IMMU Stock